XCUR - Exicure, Inc.
After hours:
| Previous close | 0.9400 |
| Open | 0.9399 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 800 |
| Day's range | 0.9200 - 0.9400 |
| 52-week range | 0.6300 - 4.9500 |
| Volume | |
| Avg. volume | 20,407 |
| Market cap | 8.116M |
| Beta (5Y monthly) | 0.97 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5800 |
| Earnings date | 09 Jun 2023 - 11 Jun 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireExicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives
CHICAGO, May 26, 2023--Exicure, Inc. (Nasdaq: XCUR) ("Exicure" or the "Company"), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, previously announced an ongoing strategy to explore strategic alternatives to maximize stockholder value, and as part of such ongoing effort, previously announced the appointment of Jung Sang (Michael) Kim as Chief Executive Officer and Chief Financial Officer of the C
Business WireExicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q
CHICAGO, May 19, 2023--Exicure, Inc., announced today it received a notice of non-compliance from Nasdaq Stock Market LLC.
Business WireExicure, Inc. Announces Investment in Korean SNS Platform Cyworld
CHICAGO, May 04, 2023--Exicure has invested in Cyworld Z Co. Ltd. through the purchase of $1 million aggregate principal amount of convertible bonds issued by Cyworld Z.
Business WireExicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors
CHICAGO, April 27, 2023--Exicure, Inc. (Nasdaq: XCUR), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today announced that, effective as of April 26, 2023, Jung-Sang (Michael) Kim was appointed as Chief Executive Officer and Chief Financial Officer of the Company and a Class II director of the Company’s board of directors (the "Board"). Mr. Kim succeeds Dr. Matthias Schroff, who yesterday steppe
Business WireExicure, Inc. Reports Full Year 2022 Financial Results and Provides Corporate Update
CHICAGO, March 27, 2023--Exicure, Inc., reported financial results for the year ended December 31, 2022 and provided an update on its business strategy and corporate progress.
Business WireExicure, Inc. Announces Closing of Private Placement Transaction with CBI USA, Inc. and Changes to the Board of Directors
CHICAGO, February 24, 2023--Exicure today announced the closing of the previously-announced private placement transaction with CBI USA, Inc. effective February 24, 2023.
Business WireExicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements
CHICAGO, December 14, 2022--Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements
Business WireExicure, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update
CHICAGO, November 14, 2022--Exicure reported financial results for the quarter ended September 30, 2022 and provided an update on its business strategy and corporate progress.
Business WireExicure, Inc. Enters Into Definitive Agreement With CBI USA, Inc. for $5.4 Million Equity Financing and Announces Implementation of Strategic Measure to Reduce Cash Burn and Prioritize Strategic Alternatives
CHICAGO, September 26, 2022--Exicure announced plans to restructure the Company and align resources to continue exploring strategic alternatives that maximize stockholder value.
Business WireExicure Announces Presentation at Chardan’s 6th Annual Genetic Medicines Conference
CHICAGO, September 01, 2022--Exicure CEO Matthias Schroff will provide a live presentation at the 2022 Chardan Genetic Medicines Conference.
Business WireExicure, Inc. Reports Second Quarter 2022 Financial Results and Corporate Progress
CHICAGO, August 15, 2022--Exicure today reported financial results for the quarter ended June 30, 2022 and provided an update on its business strategy and corporate progress.
Business WireExicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement
CHICAGO, July 20, 2022--Exicure, Inc. (Nasdaq: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that on July 19, 2022, it received a letter from the Office of General Counsel of The Nasdaq Stock Market LLC informing it that Nasdaq has confirmed that the Company has regained compliance with the $1.00 per share minimum
Business WireExicure, Inc. Announces Receipt of Nasdaq Notice of Non-compliance and Implementation of One-for-Thirty Reverse Stock Split
CHICAGO, June 29, 2022--Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that, following the implementation of a one-for-thirty reverse stock split at 5:00 p.m. EDT today, the Company’s common stock will begin trading on a split-adjusted basis on Nasdaq effective with the open of business tomor